Fig. 4From: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancerChange from baseline to day 21 in CXCR1 expression on tumor cells by IHC. The percentage of patients with each score is presented. a Extent. b Intensity. x, no tumor found on the blockBack to article page